US9528089B2ActiveUtilityA1
Method for increasing the proportion of animal cells secreting galectin-9
Est. expiryDec 9, 2030(~4.4 yrs left)· nominal 20-yr term from priority
A61P 37/08A61P 43/00A61P 5/38A61P 37/02A61P 37/06A61P 29/00A61P 31/04G01N 2333/4724G01N 33/6893A61P 31/00A61P 35/00G01N 2333/42C07K 14/4726C12N 2501/59A61P 35/02G01N 33/56972G01N 33/68A61K 49/0004A61K 38/1732G01N 33/5094G01N 2333/705A61K 40/42A61K 40/416A61K 40/35A61K 40/11A61K 40/17A61K 40/22A61K 40/24A61K 40/15A61K 40/19A61K 40/13A61K 35/17C12N 5/0639C12N 5/0645C12N 5/0637C12N 5/0646C12N 5/0635C12N 5/0636A61K 2239/46
45
PatentIndex Score
0
Cited by
86
References
14
Claims
Abstract
The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A method for increasing a proportion of animal cells capable of secreting galectin-9, the method comprising:
culturing animal cells under any of the following conditions 1) to 3):
1) in the presence of T cell receptor (TCR) stimulation,
2) in the presence of galectin-9, and
3) in the presence of both TCR stimulation and galectin-9;
and thereby increasing the proportion of animal cells capable of secreting galectin-9.
2. The method according to claim 1 , wherein the animal cells increased in proportion comprise T cells.
3. The method according to claim 2 , wherein the animal cells increased in proportion comprise CD4 positive T cells.
4. The method according to claim 3 , wherein the animal cells increased in proportion comprise follicular B helper T cells (TFH cells).
5. The method according to claim 1 , wherein the animal cells increased in proportion comprise γδT cells.
6. The method according to claim 1 , wherein the animal cells increased in proportion comprise natural killer cells (NK cells).
7. The method according to claim 1 , wherein the animal cells increased in proportion comprise B cells.
8. The method according to claim 1 , wherein the animal cells increased in proportion comprise NKT cells.
9. The method according to claim 1 , wherein the animal cells increased in proportion comprise conventional dendritic cells (cDCs).
10. The method according to claim 1 , wherein the animal cells increased in proportion comprise plasmacytoid dendritic cells (pDCs).
11. The method according to claim 1 , wherein the animal cells increased in proportion comprise pDC-like macrophages (pDC-Mφs).
12. The method according to claim 2 , wherein the animal cells increased in proportion comprise cells capable of increased CD25 expression and galectin-9 and interleukin 10 (IL-10) secretion by T cell receptor (TCR) stimulation.
13. The method according to claim 2 , wherein the animal cells increased in proportion comprise cells that do not express Foxp3.
14. The method according to claim 1 , wherein the galectin-9 cultured with the animal cells has the amino acid sequence of SEQ ID NO: 6.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.